TS-075232 — Problem Breast cancer (BC) is the most commonly diagnosed malignancy and the second leading cause of cancer-related death among women in the United States. Within its subtypes, triple-negative breast cancer (TNBC) carries the highest mortality, driven in large part by a lack of effective targeted t…

TS-075182 — PROBLEM Prostate cancer (PCa) and urothelial cancers (UC) are among the most commonly diagnosed malignancies in aging adults, and their management is characterized by prolonged, costly, and invasive surveillance pathways. Both diseases exhibit marked molecular heterogeneity that drives prognosis, t…

TS-075178 — Problem Over 30,000 Americans are diagnosed every year with multiple myeloma (MM), a disease of clonal plasma cells which accumulate in the bone marrow. Despite several treatment options, MM is still incurable, and patients inevitably relapse and develop toxicities and functional decline. Novel the…

TS-065435 — The Need: The treatment landscape for multiple myeloma (MM) demands novel, targeted solutions to improve patient outcomes. Existing therapies often fall short in addressing the complex challenges posed by MM, necessitating a more precise and effective approach. The Technology: Our technology introd…

TS-062682 — Glioblastoma (GBM) is the most common malignant brain tumor accounting for 47.7% of all brain cancers. Unfortunately, treatments are limited, and survival is poor, with approximately 40% living the first-year post-diagnosis and 17% in the second year. The Need Oncolytic viruses (OVs) are a prom…

TS-062679 — Glioblastoma (GBM) is the most common malignant brain tumor accounting for 47.7% of all brain cancers. Unfortunately, treatments are limited, and survival is poor, with approximately 40% living the first-year post-diagnosis and 17% in the second year. The Need Oncolytic viruses (OVs) are a prom…